Adamson W, Egrie J C, Browne J K, Downing M R, Eschbach W
Department of Medicine, University of Washington, Seattle.
Behring Inst Mitt. 1988 Aug(83):188-92.
End-stage renal disease (ESRD) typically is associated with severe anemia. The major contributor to the anemia appears to be the absolute or relative deficiency of erythropoietin (EPO) production by the kidney. A series of clinical trials have been conducted in the United States using recombinant human EPO (rh EPO) to treat anemic patients with ESRD. The encouraging results of the Phase I-II clinical trials have been confirmed in a multicenter trial in which over 250 patients have been treated. The results indicate that rh EPO can effectively correct the anemia of ESRD and the rate of correction is dependent upon the initial dose given. The rHuEpo was well tolerated, produced few or no direct side effects, and was effective in greater than 95 percent of the patients. rh EPO should have a major role in the correction of the anemia of ESRD and contribute significantly to the rehabilitation of such patients.
终末期肾病（ESRD）通常与严重贫血相关。贫血的主要原因似乎是肾脏促红细胞生成素（EPO）产生的绝对或相对不足。美国已开展了一系列使用重组人促红细胞生成素（rhEPO）治疗ESRD贫血患者的临床试验。I-II期临床试验的令人鼓舞的结果已在一项多中心试验中得到证实，该试验治疗了超过250名患者。结果表明，rhEPO可有效纠正ESRD贫血，纠正率取决于初始给药剂量。重组人促红细胞生成素耐受性良好，几乎没有或没有直接副作用，并且在超过95%的患者中有效。rhEPO在纠正ESRD贫血方面应发挥主要作用，并对这类患者的康复做出重大贡献。
